Dimension Therapeutics
Dimension Therapeutics was a Cambridge, Massachusetts–based clinical-stage biotechnology company. Per firmographic data it developed gene therapies for rare diseases; product data references a DCVax® dendritic-cell cancer vaccine platform with lead candidate DCVax®-L for glioblastoma. It previously traded on NASDAQ as DMTX.
- Company typePrivate
- Founded2013
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Dimension Therapeutics firmographics
Firmographics- Name
- Dimension Therapeutics
- Website
- https://dimensiontx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Dimension Therapeutics was a Cambridge, Massachusetts–based clinical-stage biotechnology company. Per firmographic data it developed gene therapies for rare diseases; product data references a DCVax® dendritic-cell cancer vaccine platform with lead candidate DCVax®-L for glioblastoma. It previously traded on NASDAQ as DMTX.
- Ownership category
- akta.pro rank
Dimension Therapeutics industry classification
Industry- Product category
- Gene Therapy / Rare Disease Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dendritic Cell & Other APC-based Therapies (HLAAABAF)
- akta.pro secondary industries
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where Dimension Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Dimension Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Dimension Therapeutics product offering
Product offeringCore offering
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases. The company builds adeno-associated virus (AAV)-based therapeutics intended to address unmet medical needs in patients with rare genetic disorders. Separately, source material also describes a dendritic cell-based cancer vaccine platform (DCVax) developed within the company, with the lead candidate DCVax-L positioned for glioblastoma.
Differentiator
Problem solved
Functional benefit
Products and services
- DCVax® Dendritic cell-based cancer vaccine platform that harnesses the patient's own immune system to target and fight cancer cells.
- DCVax®-L Lead treatment candidate from the DCVax® platform, developed for glioblastoma (a form of brain cancer). A Marketing Authorization Application (MAA) has been submitted to the UK's MHRA for regulatory review.
Companies that use Dimension Therapeutics
Customer profileIdeal customer profiles1 record
Dimension Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Dimension Therapeutics competitors and assessment
Company assessmentDirect peers
- Northwest Biotherapeutics: Developer of the DCVax platform of personalized dendritic cell-based vaccines, including DCVax-L for glioblastoma — the same technology category attributed to Dimension Therapeutics in source data, making it the most direct peer.
- Neon Therapeutics: Clinical-stage developer of personalized neoantigen vaccines (NEO-PV-01) before its acquisition by Bristol-Myers Squibb — a closely comparable personalized cancer vaccine peer.
- Dendreon: Pioneer of autologous dendritic cell therapy with Provenge (sipuleucel-T), the first FDA-approved cellular immunotherapy for prostate cancer — a directly comparable autologous dendritic cell vaccine peer.
- Sotio: Clinical-stage developer of autologous dendritic cell-based vaccines for prostate and other cancers — operates in the same APC-based therapeutic class as Dimension Therapeutics.
- Immunicum: Swedish clinical-stage biotech developing allogeneic dendritic cell-based immunotherapies for solid tumors — directly comparable dendritic cell vaccine modality.
Broad incumbents
- BioNTech: Major mRNA-based personalized cancer vaccine developer (BNT122 with Roche/Genentech). A larger, broader portfolio incumbent whose personalized immunotherapy programs compete for the same oncology positioning.
- Bavarian Nordic: Larger biopharma with active immuno-oncology and cancer vaccine programs — broader incumbent that competes for the same therapeutic vaccine market.
Emerging players
- Gritstone bio: Developer of personalized neoantigen cancer vaccines — operates in an adjacent personalized cancer immunotherapy space that competes for the same oncology vaccine market opportunity.
- VBI Vaccines: Clinical-stage biotech developing therapeutic cancer vaccines including an oncolytic vaccine program — operates in the broader therapeutic cancer vaccine category.
Others
- Ultragenyx: Commercial-stage rare disease gene therapy company with a track record of acquiring clinical-stage gene therapy assets. Relevant as both a buyer type and a thematic gene therapy / rare disease peer.
Market position
Customer concentration
Dimension Therapeutics social profiles
Digital presenceDimension Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dimension Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Dimension Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dimension Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dimension Therapeutics
What does Dimension Therapeutics do?
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases. The company builds adeno-associated virus (AAV)-based therapeutics intended to address unmet medical needs in patients with rare genetic disorders. Separately, source material also describes a dendritic cell-based cancer vaccine platform (DCVax) developed within the company, with the lead candidate DCVax-L positioned for glioblastoma.
Is Dimension Therapeutics a public or private company?
Dimension Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Dimension Therapeutics founded?
Dimension Therapeutics was founded in 2013. It employs 51 to 100 people.
Where is Dimension Therapeutics based?
Dimension Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Dimension Therapeutics's main competitors?
Direct peers on record are Northwest Biotherapeutics, Neon Therapeutics, Dendreon, Sotio and Immunicum. Broad incumbents are BioNTech and Bavarian Nordic. Emerging players are Gritstone bio and VBI Vaccines. Ultragenyx is listed as an others.
Does Dimension Therapeutics have an API?
No public API is recorded for Dimension Therapeutics.
What industry is Dimension Therapeutics in?
Dimension Therapeutics's product category is Gene Therapy / Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 541714 and its SIC code is 2836.